We conduct and support substance use research to inform evidence-based care and improve patient health and treatment outcomes. In addition to providing data and guidance to CODA, the program publishes in peer-reviewed journals, presents at national and international conferences, and participates in federally and privately funded research.
CODA’s nationally recognized Research Program has randomized over 2,000 study participants in 20 funded trials. We have collaborated with Oregon Health & Science University (OHSU), Geisel School of Medicine at Dartmouth College, University of Pittsburgh, University of Washington, Virginia Commonwealth University, Kaiser Permanente, and other institutions on research funded by the National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and other foundations and companies. Earlier clinical trials examined the use of extended-release naltrexone and buprenorphine, leading CODA to be early adopters of these FDA-approved medications for opioid use disorders.
EXIT-CJS [Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults]
This clinical trial seeks to compare the effectiveness extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder, among adults currently incarcerated in U.S. jails and prisons at different sites across the country. This is part of larger research umbrella of research done by the Justice Community Opioid Innovation Network (JCOIN) addressing the need to improve access to high-quality, evidence-based addiction treatment in justice settings. In Oregon, participants will be recruited from Clackamas and Washington County Jails. The study will look at changes in opioid use, opioid treatment outcomes and changes in additional criminal justice system involvement for each participant over a one year period after release. This study is hoping to begin recruiting participants in late Fall of 2020.
Additional details about the study can be found here: https://clinicaltrials.gov/ct2/show/NCT04219540
MOMs [Medication Treatment for Opioid Use Disorder in Expectant Mothers]
This study is designed to study mechanisms by which extended-release buprenorphine (BUP-XR) may improve mother-infant outcomes for treating opioid use disorder in pregnant women, compared to sublingual buprenorphine (BUP-SL). CODA Research is part of the Western States Node and will be a study site where participants are recruited. This study is hoping to begin recruiting participants in Fall of 2020.
Additional details regarding the study can be found here: https://clinicaltrials.gov/ct2/show/NCT03911466
ROAR [Reducing Overdose after Release from Incarceration]
This pilot intervention combines provision of medications for opioid use disorder (MOUD) with support from Certified Recovery Mentors (CRMs) to reduce overdose risk in adult female inmates when they are released from prison. The evaluation further assesses induction, acceptance and effectiveness of extended release naltrexone in a female post-prison population. CODA Inc. has recovery mentors involved in this pilot study.
Additional details regarding the study and its protocol can be found here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349469/
About our studies
CODA Research generally participates in two types of studies:
- Surveys about opinions, beliefs, or practices
- Clinical trials
Participants in any clinical trial are chosen based on eligibility. The informed consent process provides participants with clear explanations of the rights and risks prior to joining a research study.
Important things to know about our studies:
Medications or components of medications used in trials are usually FDA approved. Often, the research is testing a new application of a medication or a new combination of medications.
Compensation is always provided to research participants and is usually provided in the form of a gift card to a food/retail chain. The amount of compensation varies with the research project.
Your participation and personal information is confidential.